Skip to main content
SpringerLink
Log in

Knochenmetastasen bei gynäkologischen Malignomen

  • Chapter
  • First Online:
Knochenmetastasen

  • 1887 Accesses

Zusammenfassung

Bis zu 80% der Mammakarzinomonpatientinnen entwickeln im Laufe ihrer Erkrankung ossäre Metastasen. Die Therapie von Knochenmetastasen erfolgt in Abhängigkeit von Ausdehnung, Lokalisation und Klinik. Bisphosphonate bzw. Denosumab sind mittlerweile essenzieller Bestandteil in der Therapie des ossär metastasierten Mammakarzinoms. Sie sollten bei Erstdiagnose einer ossären Metastase begonnen werden und lebenslang fortgeführt werden. Sowohl Bisphosphonate als auch Denosumab reduzieren das Auftreten neuer ossärer Metastasen sowie skelettassoziierter Komplikationen und führen somit zu einer signifikanten Verbesserung der Lebensqualität. Neben gezielt-medikamentöser Therapie sind individuell auch strahlentherapeutische oder operative Interventionen indiziert, um die Lebensqualität und Mobilität der Tumorpatientin möglichst lange zu erhalten.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 79.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  1. Batson O (1942) The role of vertebral veins in metastatic processes. Ann Intern Med 16: 38–45

    Article  Google Scholar 

  2. Baziotis N, Yakoumakis E, Zissimopoulos A et al (1998) Strontium-89 chloride in the treatment of bone metastases from breast cancer. Oncology 55: 377–381

    Article  CAS  PubMed  Google Scholar 

  3. Body JJ, Diel IJ, Lichinitser M et al (2004) Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with with metastatic bone disease; results from two randomized, placebo-controlled phase III studies. Br J Cancer 90: 1133–1137

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423: 337–342

    Article  CAS  PubMed  Google Scholar 

  5. Coleman RE (2006) Advances in treating metastatic bone cancer: clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12: 6243s–6249s

    Article  PubMed  Google Scholar 

  6. Costelloe CM, Rohren EM, Madewell JE et al (2009) Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis. Lancet Oncol 10(6): 606–614

    Article  PubMed  Google Scholar 

  7. de Klerk JM, van het Schip AD, Zonnenberg BA et al (1996) Phase 1 study of rhenium-186-HEDP in patients with bone metastases originating from breast cancer. J Nucl Med 37: 244–249

    CAS  PubMed  Google Scholar 

  8. Domchek SM, Younger J, Finkelstein DM et al (2000) Predictors of skeletal complications in patients with metastatic breast carcinoma. Cancer 89(2): 363–368

    Article  CAS  PubMed  Google Scholar 

  9. Hamaoka T, Madewell JE, Podoloff DA et al (2004) Bone imaging in metastatic breast cancer. J Clin Oncol 22(14): 2942–2953

    Article  PubMed  Google Scholar 

  10. Hofbauer LC, Schoppet M (2004) Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 292: 490–495

    Article  CAS  PubMed  Google Scholar 

  11. Hortobagyi GN, Theriault RL, Porter L et al (1996) Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 335(24): 1785–1791

    Article  CAS  PubMed  Google Scholar 

  12. Hortobagyi GN, Theriault RL, Lipton A et al (1998) Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group J Clin Oncol 16(6): 2038–2044

    CAS  Google Scholar 

  13. Hughes DE, Wright KR, Uy HL et al (1995) Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10: 1478–1487

    Article  CAS  PubMed  Google Scholar 

  14. James JJ, Evans AJ, Pinder SE et al (2003) Bone metastases from breast carcinoma: histopathological-radiological correlations and prognostic features. Br J Cancer 89(4): 660–665

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Lacey DL, Timms E, Tan HL et al (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165–176

    Article  CAS  PubMed  Google Scholar 

  16. Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nature Rev Cancer 2: 584–593

    Article  CAS  Google Scholar 

  17. Mystakidou K, Stathopoulou E, Parpa E et al (2008) Oral versus intravenous ibandronic acid: a comparison of treatment options for metastatic bone disease. J Cancer Res Clin Oncol 134(12): 1303–1310

    Article  CAS  PubMed  Google Scholar 

  18. Paterson AH, Powles TJ, Kanis JA et al (1993) Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11(1): 59–65

    CAS  PubMed  Google Scholar 

  19. Purohit OP, Radstone CR, Anthony C et al (1995) A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. Br J Cancer 72(5): 1289–1293

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  20. Roodman GD (2004) Mechanisms of bone metastasis. New Engl J Med 350: 1655–1664

    Article  CAS  PubMed  Google Scholar 

  21. Rosen LS, Gordon D, Kaminski M et al (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7(5): 377–387

    CAS  PubMed  Google Scholar 

  22. Sato M, Grasser W, Endo N et al (1991) Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Investigation 88: 2095–2105

    Article  CAS  Google Scholar 

  23. Serafini AN (2001) Systemic metabolic radiotherapy with samarium-153 EDTMP for the treatment of painful bone metastasis. Q J Nucl Med 45: 91–99

    CAS  PubMed  Google Scholar 

  24. Stopeck AT, Lipton A, Body JJ et al (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28: 5132–5139

    Article  CAS  PubMed  Google Scholar 

  25. Therapieempfehlungen der AGO Mamma (2013) Kapitel Endokrine und zielgerichtete Therapie des metastasierten Mammakarzinoms. http://www.ago-online.de/de/fuer-mediziner/leitlinien/mamma

  26. Theriault RL, Lipton A, Hortobagyi GN et al (1999) Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 17(3): 846–854

    CAS  PubMed  Google Scholar 

  27. Van Poznak CH, Temin S, Yee GC et al (2011) American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 29(9): 1221–1227

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Universitätsfrauenklinik Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Deutschland

    Tanja Fehm

  2. Universitätsklinikum des Saarlandes, Klinik für Frauenheilkunde, Geburtshilfe und Reproduktionsmedizin, Kirrberger Straße, 66424, Homburg, Deutschland

    Erich Solomayer

Authors
  1. Tanja Fehm
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Erich Solomayer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tanja Fehm .

Editor information

Editors and Affiliations

  1. Universitätsklinik für Urologie, Universitätsklinikum Tübingen, Tübingen, Germany

    Arnulf Stenzl

  2. Universitätsfrauenklinik Düsseldorf, Düsseldorf, Germany

    Tanja Fehm

  3. Medizinische Klinik III, Bereich Endokrinologie, Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Germany

    Lorenz C. Hofbauer

  4. Orthopädisches Zentrum für Muskuloskelettale Forschung, Universität Würzburg, Würzburg, Germany

    Franz Jakob

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Fehm, T., Solomayer, E. (2014). Knochenmetastasen bei gynäkologischen Malignomen. In: Stenzl, A., Fehm, T., Hofbauer, L., Jakob, F. (eds) Knochenmetastasen. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-43471-0_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-43471-0_13

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-43470-3

  • Online ISBN: 978-3-662-43471-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation